BXQ-350 not checked

Bexion Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
5 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for…”In the company’s words, NCT05322590 on ClinicalTrials.gov
Tested for
Metastatic Colorectal Carcinoma, Neuropathy
Main trialPhase 1/2
“The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7. All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be…”In the company’s words, NCT05322590 on ClinicalTrials.gov
Other names
SapC-DOPS

Other drugs for Metastatic Colorectal Carcinoma

All 392 drugs for Metastatic Colorectal Carcinoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting Nov 2026 BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
Phase 1Completed 17 Jun 2019 Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
Phase 1Terminated 3 Jan 2020 A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
Phase 1Terminated 23 Sep 2024 Continued Treatment for Participants Enrolled in Studies of BXQ-350
Phase 1Terminated 4 Oct 2024 A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BXQ-350

Following is part of Solo: you see every change to BXQ-350 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in